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Objective: Psychomotor abnormalities are relevant symptoms in the clinical presentation of
schizophrenia, and assessing them could facilitate monitoring. New technologies can measure
psychomotor activity objectively and continuously, but evidence on the topic is scarce. Our aim is to
systematically review the existing evidence about eHealth tools for assessing psychomotor activity in
patients diagnosed with schizophrenia.
Method: We performed a systematic search of the PubMed and Embase databases and identified
15 relevant articles on eHealth tools for assessing psychomotor activity in schizophrenia.
Results: eHealth devices accurately assessed psychomotor activity and were well accepted.
Abnormalities in psychomotor activity helped differentiate between different subtypes of schizo-
phrenia. Abnormal increases in psychomotor activity were correlated with acute presentations, while
lower activity was associated with relapses, deterioration, and negative symptoms.
Conclusion: Actigraphy is still the preferred eHealth device in research settings, but mobile
applications have great potential. Further studies are needed to explore the possibilities of
psychomotor monitoring and mobile health applications for preventing relapses in schizophrenia.
eHealth could be useful for monitoring psychomotor activity, which might help prevent relapses.
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Introduction
Schizophrenia affects more than 21 million people around
the world and is associated with high rates of disability
and reduced life expectancy.1 Aberrant motor function is a
common feature of schizophrenia. Psychomotor abnorm-
alities (e.g., catatonia, extrapyramidal symptoms, lower
psychomotor activity, and motoric neurological soft signs)
are associated with poor prognosis and can be an early
indicator of decompensation.2,3 Thus, they could be exp-
loited for secondary prevention, which is one of the most
sought-after goals in schizophrenia management, since
relapses have a great impact on disease progression.4
Motor symptoms can also be a side effect of antipsy-
chotic medications. Although the introduction of second-
generation antipsychotics has reduced the risks, they
are still prevalent: drug-induced extrapyramidal symp-
toms reach 15% for dystonia, 16% for akathisia, and 29%
for parkinsonism.5 Psychomotor activity can alert us to
potentially serious side effects of antipsychotic medica-
tion. Patients may fail to identify the exact nature of their
discomfort, which could delay diagnosis of extrapyramidal
side effects. Switching to a different antipsychotic or mini-
mizing the side effects with co-adjuvant strategies could
prevent treatment discontinuation, a major issue in schi-
zophrenia patients.6 Reduced psychomotor activity could
also indicate a deterioration in other aspects of physical
health, such as an increased risk of metabolic syndrome.7
Nursing professionals play a major role in monitoring
the mental and physical status of patients, assessing the
side effects of medication and encouraging good treat-
ment adherence. Reliable tools for measuring psycho-
motor activity can be very helpful for these purposes,
especially if they allow continuous symptom monitoring.
However, the availability of tools to objectively assess
psychomotor-related variables is very limited. Assess-
ment usually involves psychometric scales and clinical
observations, whose subjectivity is susceptible to bias.
Psychomotor assessment in schizophrenia can be faci-
litated through the use of new technologies. Applying
digital devices to healthcare settings, which is called
electronic health or eHealth, is opening new prospects in
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the management and prevention of mental disorders.8,9
The potential of eHealth has increased thanks to conti-
nuous improvements in sensor precision and the wide-
spread availability of eHealth tools, such as smartphones,
wearable devices, and virtual reality platforms.10
eHealth interventions show excellent rates of accept-
ability and usability. For instance, it is estimated that over
60% of patients who have suffered from a psychotic epi-
sode support the use of mobile applications for monitoring
their condition, and the daily usage rate for those who
have them is over 85%. The sensors of wearable techno-
logies, smartphones and other devices can provide infor-
mation on user mobility (location, frequency of movement
and distance travelled) and psychomotor activity (move-
ment and acceleration). By integrating this information
with data from other sources, increasingly complex vari-
ables can be inferred. Moreover, through machine learn-
ing, mobile applications can infer the association between
certain behavior patterns and clinical decompensation.11
In the past few years, there has been an increasing
interest in these technologies in mental health settings,
but the continuous development of new technologies
is advancing much faster than empirical research on
them.12 It is crucial to review the evidence about such
tools to provide the best evidence-based knowledge for
good use of this technology. This is the first review on this
topic. Our aim is to systematically review the existing
evidence about eHealth tools for assessing psychomotor
activity in schizophrenia.
Methods
This review complied with the applicable Preferred
Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) guidelines.13
Inclusion/exclusion criteria
The inclusion criteria were: 1) articles published in peer-
reviewed journals; 2) articles that included adults diag-
nosed with schizophrenia in their sample; 3) articles that
explored any kind of eHealth tool (mobile apps, wearable
devices, computer software, virtual reality devices, acti-
graphs, video games) to evaluate psychomotor variables.
Proofs of concept, protocols for original studies, n=1 case
studies, and articles that did not provide measurable
outcomes were excluded.
Search strategy
We conducted a systematic literature search in the
PubMed and Embase databases whose final search date
was January 21st, 2020. There were no restrictions regard-
ing publication date, although only publications in English
or Spanish were selected for review. For the search stra-
tegy, we used combinations of three groups of terms: one
group to refer to eHealth, another for psychomotor vari-
ables, and a third focusing on schizophrenia diagnosis.
The following search terms were used (in any field):
((ehealth OR mhealth OR technology OR actigraph OR
phone OR app OR virtual reality OR video game OR
videogame OR wearables OR computer) AND (psycho-
motor OR movement OR motor OR mobility OR physical
activity) AND (schizophrenia OR psychosis OR psychotic
OR schizophrenic)). The references of included studies
were also screened.
Study selection process
The publications were assessed independently by two
researchers (APS and RM). Articles were selected
according to their relevance and quality. We used critical
appraisal checklists to assess study quality.14 Conflicts
were resolved through a third author (EBG), who made
the final decision. Agreement between reviewers, mea-
sured by intraclass correlation coefficient (ICC), was 0.80
(95% confidence interval [95%CI] 0.69-0.88).
Data extraction
Data were collected by two independent authors (APS
and RM) using previously developed forms. Data on the
following variables were collected: author, study design,
year of study publication, device, psychometric tools, and
main findings.
Results
Results of the bibliographical search
The initial search revealed 1,251 results. After content
analysis, 15 articles were included in the review. Figure 1
shows the flow chart of the systematic search.
Study characteristics
The sample sizes ranged between 1115 and 148 partici-
pants.16 The main findings of the reviewed studies are
shown in Table 1.15-29 Eleven of the studies included only
psychotic patients in the case group, while four used
mixed psychiatric samples with different diagnoses –
including schizophrenia. Most studies recruited stable
patients with no recent psychopathological decompensa-
tions, while a few included patients who were at high risk
or who had been admitted to acute inpatient psychiatric
units.23
Wearable devices
In 11 of the reviewed articles, movement was assessed
through actigraphy. In most of them, the actigraph was




, a wrist-worn actigraphy-equipped device
developed by Cambridge Neurotechnology, was the most
common device used in these studies. Walther et al. meas-
ured psychomotor activity over 24 hours in 55 patients using
the Actiwatch, and then compared the results with the
patients’ Positive and Negative Syndrome Scale (PANSS)
scores, finding that high scores in PANSS-assessed nega-
tive symptoms correlated with low levels of actigraphy-
measured motor activity. In contrast, specific motor-related
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items of the PANSS scale were not significantly associated
with their corresponding actigraphic parameters.16 Also
using the Actiwatch, Welther et al. found that differences in
physical activity accurately discriminated between first psy-
chotic episode and subsequent outbreaks in those diag-
nosed with schizophrenia, with lower activity indicating
greater deterioration.
A different wearable device, the SenseWear Pro3 Arm-
band was used to assess sedentary behavior in patients
diagnosed with schizophrenia, and good correlation was
found between this assessment tool and traditional tests,
such as the 6-minute walk test, regarding the physical
component of the Health-Related Quality of Life.20
Other eHealth tools
Three of the reviewed studies used mobile apps, either
alone or in combination with actigraphy. Barnett et al.
followed 17 adults diagnosed with schizophrenia for
3 months, using passively collected smartphone data on
mobility and social activity to predict relapses. They found
that behavioral abnormalities were 71% higher at the
moment of relapse than during periods of stability.18 Kluge
et al. used a combination of Ecological Momentary
Assessment (EMA) and actigraphy to measure motor
activity and explore its association with apathy. They found
that objectively measured motor activity was a better
correlate of apathy than daily activities subjectively asses-
sed through EMA. They also found that alterations detec-
ted by actigraphy had different neurobiological correlates
than those detected by EMA.25
Two studies used video recording and analysis soft-
ware to objectively assess psychomotor activity. Dean
et al. chose this approach to characterize young adults at
high risk of psychosis, finding that motor activity accu-
rately differentiated them from age-matched healthy
controls.23 Dutschke et al. also used video recording with
automatized analysis, finding differences in gesture per-
formance between cases and controls.24
Feasibility
Actigraphy and inertial movement sensors yielded gene-
rally good results in terms of user acceptance and enga-
gement, with few drop-outs over the follow-up periods. In
some studies, patients received some kind of monetary
compensation for participating.25 The most commonly
reported causes for dropout were: failure to engage with
Figure 1 Flow chart of the bibliographic search.
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the device/application for several days in a row,20,25,26




We found few articles exploring new technologies for
assessing psychomotor activity in schizophrenia. This is a
neglected field of study that should receive further atten-
tion in future research.
Psychomotor abnormalities in schizophrenia
Psychomotor variables are highly correlated with relevant
aspects of schizophrenia. Since psychomotor symptoms
can help predict a first psychiatric episode and are
predictors of high risk for psychosis, they might also be
used as markers to predict changes in the clinical course
of the disease. Early detection and treatment of the first
psychotic episode and subsequent relapses greatly imp-
roves prognosis.
In our review, an abnormal increase in psychomotor
activity was correlated with acute presentations, while
lower activity was associated with deterioration. Abnorm-
alities in psychomotor activity also helped differentiate
between different subtypes of schizophrenia patients.
These findings could be related to the different physio-
pathological mechanisms underlying schizophrenia and
may shed some light on the neurobiological correlates of
the disorder.
The differences in motor activity between depression
and schizophrenia patients found in one of the studies
suggest that these motor symptoms are more than
a non-specific consequence of severe mental illness.
In research settings, these symptoms may yield more
clinically-relevant data than other transdiagnostic symp-
toms, such as sleep. Improved measures and the avai-
lability of more tools for objective mobility assessment, as
well as the possibility of continuous monitoring, make
psychomotor activity a valuable source of information that
is underused in research.
Barriers to using eHealth
Despite good acceptability rates, there are still several
barriers to using eHealth among psychiatric patients. One
is that eHealth has not been integrated into public health
systems, which can raise suspicions about its reliability
and effectiveness and limit access to interventions.30
Although a few health systems, such as the UK’s National
Health System, are beginning to integrate eHealth as a
therapeutic tool in health care coverage, this is the excep-
tion rather than the rule.31 Privacy concerns have also
been associated with patient reluctance to use eHealth.32
In agreement with previous reviews, we found that
eHealth interventions are generally well accepted by
individuals diagnosed with schizophrenia.33 Most apps
have had good rates of engagement, with few dropouts
during follow-up. However, one potential bias is that the
samples predominantly consisted of stable patients, since
they are more likely to participate. Another potential
bias involves the use of incentives, i.e. monetary or other
rewards for participating in studies and engaging with the
devices. Since patients will not be rewarded for using the
device in real world settings, the application of these
findings in clinical practice could be limited.
Implications for clinical practice
eHealth tools could be especially apt for detecting relap-
ses through continuous monitoring of psychomotor-
related symptoms. Mobile phone ownership among people
with psychosis is estimated to be between 66 and 81% and
is rapidly increasing.34,35 The increasing reliability of the
devices’ sensors further expands their potential. Movement
could be a feasible and reliable digital biomarker of decom-
pensation and could be used in relapse prevention. This
also represents a step towards precision medicine.8 How-
ever, most of the reviewed studies recommended actigra-
phy for objective measurement of movement. More studies
with larger sample sizes are required to confirm this
hypothesis.
The role of nursing staff in the implementation of eHealth
tools
Nursing professionals can be crucial in overcoming
these barriers and facilitating eHealth use in psychiatric
patients.36 Since psychiatric patients tend to create strong
bonds with nursing professionals, whom they usually
perceive as less threatening, they may trust their recom-
mendations.36 Another way to spread eHealth in psychia-
tric settings is by encouraging patients and their fami-
lies to participate in designing and implementing usage
strategies.37
Limitations
Our findings must be considered in light of some limi-
tations. Firstly, due to the composition of our research
team, the search had to be language-restricted to Spanish
or English. Secondly, the variety of terms for new techno-
logies, which are becoming more numerous and varied,
may have led us to overlook some tools that would fit within
the eHealth umbrella. Finally, the exponential growth in
available evidence will render any reviews in this field
quickly outdated.
Conclusions
Although eHealth-based mobility assessment is still at an
early stage of development, eHealth tools were found to
be generally accurate assessment methods in the revie-
wed studies. One factor that can influence precision is the
placement of the wearable device. Devices are usually
attached to the non-dominant wrist, since measures from
the dominant wrist might reflect low-energy demanding
manual tasks rather than whole body movement. Placing
devices on different parts of the body (e.g. the chest, hip,
or waist) risks less sensitivity to activities performed while
Braz J Psychiatry. 2021;43(1)
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sitting. Technological advancements and optimizing these
devices for use in clinical practice can improve precision
in the next few years.
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